Skip to Content Facebook Feature Image

Flaus, the World’s Best Electric Flosser and Now the Only Clinically Backed Electric Flosser on the Market, Completes Successful Clinical Trials, Proving That It Removes More Plaque Between Teeth Than ADA Approved, Traditional String Floss

News

Flaus, the World’s Best Electric Flosser and Now the Only Clinically Backed Electric Flosser on the Market, Completes Successful Clinical Trials, Proving That It Removes More Plaque Between Teeth Than ADA Approved, Traditional String Floss
News

News

Flaus, the World’s Best Electric Flosser and Now the Only Clinically Backed Electric Flosser on the Market, Completes Successful Clinical Trials, Proving That It Removes More Plaque Between Teeth Than ADA Approved, Traditional String Floss

2026-02-23 20:03 Last Updated At:20:10

NEW YORK--(BUSINESS WIRE)--Feb 23, 2026--

Flaus, a DTC oral beauty brand, revolutionizing oral care with its inaugural product, the award-winning first of its kind electric flosser, is proud to announce that after conducting a clinical study: “The Evaluation of Interdental Plaque Removal Efficacy of Flaus® Electric Flosser compared to Brushing Alone and String Floss,” by J Milleman, K Milleman, S Santos, A Yoder, T Grahovac, K Wills, T Eads of SLS Clinical Research Consulting, it has been clinically proven to remove over 7 times more plaque between teeth when compared to ADA approved, traditional string floss. Flaus is the only clinically backed electric flosser on the market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223775628/en/

The study concluded that using Flaus in addition to brushing for two minutes with a standard manual toothbrush resulted in significantly greater plaque removal between teeth:

“When we built Flaus, clinical validation wasn't optional - it was everything,” explained Flaus Founder and CEO, Samantha Coxe. “Being the only clinically-backed electric flosser on the market hasn't just differentiated us; it's forced an industry to answer a question it had been avoiding for decades: why haven't we held flossing to the same standard as brushing? We didn't just build a better product. We raised the bar - and now there's no going back.”

The objective of the study was to evaluate the plaque removal efficacy of flossing at night using Flaus versus traditional, string floss - both, while still using a manual soft toothbrush - compared to just brushing alone. The clinical study was conducted by SLS Clinical Research Consulting at Salus Research in Fort Wayne, Indiana. Key components of the study are outlined below.

Notable conclusions also showed that string floss plus manual tooth brushing did not differ significantly from manual tooth brushing alone in removing plaque. Brushing with a standard manual toothbrush only did not remove clinically significant levels of plaque. String floss plus manual tooth brushing did not provide any plaque removal benefit over that provided by brushing alone.

Compared to pre-brushing plaque scores, proximal (between teeth) surface reductions were:

Flossing has long been tied to outcomes far beyond oral health - from heart disease and diabetes to Alzheimer's and dementia. Yet 60% of Americans don't floss regularly, 30% don't floss at all, and 27% of those who say they do admit they're not being truthful. Compliance, not knowledge, has always been the problem.

The Flaus electric flosser was designed to solve exactly that. Its 18,000 sonic vibrations per minute, ergonomic silicone handle, and 60-second routine have driven a 90% compliance rate among customers - compared to the near-universal avoidance of string floss. The clinical data now confirms that the tool driving compliance is also the tool actually removing plaque.

The device was also built with accessibility at its core. For people managing arthritis, stroke recovery, cerebral palsy, or limb differences - for whom traditional string flossing has never been a realistic option - Flaus offers a clinically effective alternative. The packaging incorporates braille. The one-button design and ergonomic handle make it possible to reach back molars without requiring fine motor precision.

Details of proximal plaque removal are provided in Table 1 above. The plaque removal effect on other tooth surfaces such as gumline and whole mouth (all tooth surfaces) is presented in Table 1.

Key components of the study:

To read this study, please visit: https://cdn.shopify.com/s/files/1/0529/8202/2332/files/Flaus_Electric_Flosser_Clinical_Trial_Results.pdf?v=1771378307

ABOUT FLAUS:

Flaus {Pronunciation: Fl-ow-s (rhymes with house)} is a DTC oral beauty brand, revolutionizing oral care with the world’s best electric flosser - the electric toothbrush of flossing and fun. We all know that self-care is important and we spend time on all the things around our teeth, but we don't give our teeth the same intentional care as we do the rest of our face. Your toothbrush only cleans 60% of your teeth - the other 40% - that's where flossing comes in. Flossing has huge implications on your entire overall health. From Heart and brain health to blood sugars - not flossing has been tied to acne, oral cancer, diabetes, heart disease, Dementia and Alzheimer's.

Flaus was created with people and the planet in mind, and is recognized as a certified Public Benefit Corp operating in a responsible and sustainable manner focused on generating both social + public good. Flaus’ floss heads are made with recyclable plastic and use 30% less plastic than typical dental picks. As more than 3M miles of floss end up in landfills annually, Flaus offers a free recycling program for used floss heads to address the sustainability issue at the oral care markets’ core.

Flaus sold-out 5x’s in the first 12 months of launching and now comes in three colors: black, white and pink, as well as matching travel cases and mirror mounts. Flaus was featured on the season 15 finale of ABC’s “Shark Tank” - leading to a bidding war and ultimately a deal with guest Shark, Candace Nelson and was selected as one of Oprah’s Favorite Things 2025. Flaus also won TIME’S Best Inventions and Fast Company’s World Changing Ideas. Flaus is on a mission to help people keep their teeth for life by transforming flossing from a dreadful chore into a delightful ritual. After all, your smile is your greatest asset.

For more information about Flaus, please visit www.goflaus.com and follow us on Instagram @goflaus.

ABOUT FOUNDER, SAMANTHA COXE:

Flaus is female-owned and operated. Samantha Coxe, creator of Flaus, revolutionized oral care by inventing the world's first electric flosser. After struggling with traditional flossing and facing 10 cavities at a dental visit, she realized the need for innovation. Drawing inspiration from her electric toothbrush experience, Coxe left her successful career as a mergers and acquisitions lawyer at Skadden, Arps to develop the world's first electric flosser, Flaus. Named one of Inc.'s Top 250 Female Founders, Coxe holds a Doctor of Law from NYU, attended USC for undergrad, and currently lives in New York City.

Table 1

Table 1

Flaus, the World’s Best Electric Flosser and Now the Only Clinically Backed Electric Flosser on the Market, Completes Successful Clinical Trials, Proving That It Removes More Plaque Between Teeth Than ADA Approved, Traditional String Floss

Flaus, the World’s Best Electric Flosser and Now the Only Clinically Backed Electric Flosser on the Market, Completes Successful Clinical Trials, Proving That It Removes More Plaque Between Teeth Than ADA Approved, Traditional String Floss

Flaus, the World’s Best Electric Flosser and Now the Only Clinically Backed Electric Flosser on the Market, Completes Successful Clinical Trials, Proving That It Removes More Plaque Between Teeth Than ADA Approved, Traditional String Floss

Flaus, the World’s Best Electric Flosser and Now the Only Clinically Backed Electric Flosser on the Market, Completes Successful Clinical Trials, Proving That It Removes More Plaque Between Teeth Than ADA Approved, Traditional String Floss

ST. LOUIS--(BUSINESS WIRE)--Feb 23, 2026--

Bruker Corporation (Nasdaq: BRKR) today announced new advancements to enable Functional Proteomics 2.0 workflows on the timsOmni™ mass spectrometer to enable disease researchers to move beyond canonical protein lists toward biologically or pathologically functional proteoforms and PTM-resolved peptide variants. New releases in Bruker ProteoScape ™, OmniScape ™, and GlycoScape ™ software now support database-independent PTM discovery, confident proteoform characterization, and eXd-enabled glycoproteomics for deeper biological, disease and drug discovery insights.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223057286/en/

Similarly, the now enabled timsOmni deep proteoform methods are equally powerful in interrogating drug targets, as well as biologics, including therapeutic antibodies, ADCs, multispecifics, and their PTM distributions and glyco-heterogeneity.

Confident proteoform characterization and eXd-enabled glycoproteomics on timsOmni

The latest version OmniScape™ 2026b strengthens timsOmni proteoform workflows by integrating the novel OmniWave™ algorithm, which enables top-down sequencing and proteoform identification at scale with high-confidence annotation of critical PTMs that drive disease signaling. Researchers can now move beyond protein group read-outs to proteoform-centric mechanisms, e.g., distinguishing signaling relevant protein variants that indicate disease states or treatment response. In biotherapeutics research, OmniScape supports verification of expected sequences and non-canonical modifications and can flag sequence variants or heterogeneity that may affect side effects or efficacy.

Bruker is greatly enhancing glycoproteomics with support for trapped electron‑based dissociation (eXd) data in GlycoScape software, enabling confident glycopeptide characterization while preserving fragile glycan structures and supporting localization and topology insights. GlycoScape also provides interactive visualization of eXd fragment ions within annotated MS/MS spectra to simplify the validation of results.

“The timsOmni gives scientists access to eXd-enabled fragmentation that can resolve complex PTMs and proteoforms with outstanding fidelity,” said Professor Yehia Mechref, Director of the Texas Tech University Center for Biotechnology & Genomics. “The new software capabilities—especially eXd N-glycopeptide analysis and improved top-down workflows—support deeper understanding of disease biology and provide new avenues for target discovery and translational research.”

Bruker ProteoScape™ adds AI‑enhanced de novo peptide sequencing for database‑independent discovery in metaproteomics and immunopeptidomics

Bruker is introducing a new de novo peptide sequencing workflow in Bruker ProteoScape v2026b software that pairs an AI‑enhanced scoring model—trained on more than seven million MS/MS spectra—with a proven dynamic‑programming foundation to deliver accurate de novo sequences from high‑resolution timsTOF data. This supports the demand for database‑independent proteomics, enabling discovery of peptide variants across complex samples in applications such as metaproteomics and immunopeptidomics, including neoantigen research in immuno-oncology.

“Researchers are increasingly studying biological systems where reference databases alone do not capture the true molecular diversity,” said Bin Ma, founder of Rapid Novor Inc. “Our collaboration with Bruker has enabled Novor.AI to take advantage of large, high-quality timsTOF datasets and combine them with our AI model to deliver the speed, confidence, and precision needed for next-generation de novo peptide sequencing applications.”

About Bruker Corporation – Leader of the Post-Genomic Era

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in specialty diagnostics, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Significantly improved de novo inference of peptide sequences from complex high-resolution timsTOF data with Bruker ProteoScape™

Significantly improved de novo inference of peptide sequences from complex high-resolution timsTOF data with Bruker ProteoScape™

Annotated timsOmni™ glycopeptide eXd spectrum from GlycoScape™ highlighting both glycan fragment ions as well as peptide fragment ions

Annotated timsOmni™ glycopeptide eXd spectrum from GlycoScape™ highlighting both glycan fragment ions as well as peptide fragment ions

Recommended Articles